Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 8/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.62 |
| ▸ | USP2 | O75604 | 10/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 9/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13894997 | 0.93 | PTGDR (0.83) | PTGDRCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL9912251 | 0.91 | PTGDR (0.61) | PTGDRCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4501568 | 0.91 | PTGDR (0.85) | PTGDRCYP1A2CYP3A4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL4494540 | 0.90 | PTGDR (0.84) | PTGDRCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4495558 | 0.86 | PTGDR (0.77) | PTGDRCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4502140 | 0.83 | PTGDR (1.00) | PTGDRCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4499080 | 0.83 | PTGDR (0.76) | PTGDR | |
| Hydrochloric Acid SCHEMBL4495692 | 0.83 | PTGDR (0.98) | PTGDRCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4487946 | 0.79 | PTGDR (0.65) | PTGDR | |
| SCHEMBL9912269 | 0.78 | PTGDR (0.80) | PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193183-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-7517889-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | PTGDR 8/4885CYP1A2 273/4885CYP3A4 1544/4885 |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | PTGDR 8/4885CYP1A2 273/4885CYP3A4 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.